Evidence map›Paper›PMID 28640871›Full record

ArticlePloS one2017

Nomogram to predict rectal toxicity following prostate cancer radiotherapy.

Jean-Bernard Delobel, Khemara Gnep, Juan David Ospina, Véronique Beckendorf, Ciprian Chira, Jian Zhu, Alberto Bossi, Taha Messai, Oscar Acosta, Joël Castelli and 1 more

Registry-linked trialAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05880446 (PROstate CAncer Radiotherapy), which is not on this map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05880446 nacompletednot on this mapstarted 2023, after this paper: background citation

PROstate CAncer Radiotherapy: Its Real Impact on Bowel Symptoms & Quality of Life Today, Measured by the EORTC QLQ C30 & Specific PRT20 Module.

TypeinterventionalSponsorJules Bordet InstituteRan2023 to 2024Enrolled41ConditionsProstate Cancer, Radiotherapy Side Effect, Bowel Dysfunction, Quality of LifeArmsBowel symptoms & QoL assessment
3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Journal of clinical medicine · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Assessment of rectal toxicities after radiation therapy for localized prostate cancer: experience of the Akanda Cancer Institute in Gabon.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jean-Bernard DelobelDept. of Gastroenterology, Centre Hospitalier Universitaire Pontchaillou, Rennes, France.
Khemara GnepLTSI, Inserm U1099, Université de Rennes 1, Rennes, France.ORCID http://orcid.org/0000-0002-9004-1652
Juan David OspinaLTSI, Inserm U1099, Université de Rennes 1, Rennes, France.
Véronique BeckendorfCentre Alexis Vautrin, Vandoeuvre les Nancy, France.
Ciprian ChiraCentre Alexis Vautrin, Vandoeuvre les Nancy, France.
Jian ZhuLTSI, Inserm U1099, Université de Rennes 1, Rennes, France.
Alberto BossiInstitut Gustave-Roussy, Villejuif, France.
Taha MessaiInstitut Gustave-Roussy, Villejuif, France.
Oscar AcostaLTSI, Inserm U1099, Université de Rennes 1, Rennes, France.
Joël CastelliLTSI, Inserm U1099, Université de Rennes 1, Rennes, France.
Renaud de CrevoisierLTSI, Inserm U1099, Université de Rennes 1, Rennes, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo identify predictors of acute and late rectal toxicity following prostate cancer radiotherapy (RT), while integrating the potential impact of RT technique, dose escalation, and moderate hypofractionation, thus enabling us to generate a nomogram for individual prediction.

methodsIn total, 972 patients underwent RT for localized prostate cancer, to a total dose of 70 Gy or 80 Gy, using two different fractionations (2 Gy or 2.5 Gy/day), by means of several RT techniques (3D conformal RT [3DCRT], intensity-modulated RT [IMRT], or image-guided RT [IGRT]). Multivariate analyses were performed to identify predictors of acute and late rectal toxicity. A nomogram was generated based on the logistic regression model used to predict the 3-year rectal toxicity risk, with its accuracy assessed by dividing the cohort into training and validation subgroups.

resultsMean follow-up for the entire cohort was 62 months, ranging from 6 to 235. The rate of acute Grade ≥2 rectal toxicity was 22.2%, decreasing when combining IMRT and IGRT, compared to 3DCRT (RR = 0.4, 95%CI: 0.3-0.6, p<0.01). The 5-year Grade ≥2 risks for rectal bleeding, urgency/tenesmus, diarrhea, and fecal incontinence were 9.9%, 4.5%, 2.8%, and 0.4%, respectively. The 3-year Grade ≥2 risk for overall rectal toxicity increased with total dose (p<0.01, RR = 1.1, 95%CI: 1.0-1.1) and dose per fraction (2Gy vs. 2.5Gy) (p = 0.03, RR = 3.3, 95%CI: 1.1-10.0), and decreased when combining IMRT and IGRT (RR = 0.50, 95% CI: 0.3-0.8, p<0.01). Based on these three parameters, a nomogram was generated.

conclusionsDose escalation and moderate hypofractionation increase late rectal toxicity. IMRT combined with IGRT markedly decreases acute and late rectal toxicity. Performing combined IMRT and IGRT can thus be envisaged for dose escalation and moderate hypofractionation. Our nomogram predicts the 3-year rectal toxicity risk by integrating total dose, fraction dose, and RT technique.

Indexed as

NomogramsAdultAgedAged, 80 and overDose-Response Relationship, RadiationHumansMaleMiddle AgedProstatic NeoplasmsRadiotherapy, Image-GuidedRadiotherapy, Intensity-ModulatedRectumRisk AssessmentTime Factors

Identifiers

PMID28640871
PMCPMC5480987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.